| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
|
Medicine details |
|
| Medicine name | larotrectinib (Vitrakvi®) |
| Formulation | 20 mg/ml oral solution, 25 mg and 100 mg hard capsule |
| Reference number | 3748 |
| Indication | As monotherapy for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options |
| Company | Bayer Healthcare Pharmaceuticals |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/08/2019 |
| NICE guidance | TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Commercial arrangement | PAS + CAA |